NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.

NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.